Teva Pharmaceutical Industries Limited
TEVJFOTCHealthcare● Active
$30.34
+$0.15(+0.50%)
Market Cap$35.3B
P/E Ratio—
52W High$32.84
52W Low$14
Teva Pharmaceutical Industries Limited (TEVJF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TEVJF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$0.50
Est. $0.45 · +10.3%
Revenue
$3.76B
Est. $3.64B · +3.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
TEVJF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.61 | — | — | — | $4.11B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $0.45 | $0.50 | +10.3% | $3.76B | $3.64B | +3.2% |
| ▲ Q1 FY2026 | Jan 28, 2026 | $0.64 | $0.93 | +46.2% | $4.58B | $4.28B | +7.0% |
| ▼ Q3 FY2025 | Jul 30, 2025 | $0.62 | $0.24 | -60.6% | $4.18B | $4.36B | -4.3% |
| ▼ Q2 FY2025 | May 7, 2025 | $0.46 | $0.18 | -59.5% | $3.89B | $4.38B | -11.2% |
| ▼ Q1 FY2025 | Jan 29, 2025 | $0.70 | -$0.19 | -127.5% | $4.23B | $4.09B | +3.3% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $0.66 | -$0.39 | -158.1% | $4.33B | $4.16B | +4.1% |
| ▼ Q3 FY2024 | Jul 31, 2024 | $0.54 | -$0.74 | -237.4% | $4.10B | $3.93B | +4.5% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.61
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$0.50
EPS Est.
$0.45
EPS Surpr.
+10.3%
Revenue
$3.76B
Q1 FY2026
Jan 28, 2026Beat
EPS Actual
$0.93
EPS Est.
$0.64
EPS Surpr.
+46.2%
Revenue
$4.58B
Q3 FY2025
Jul 30, 2025Miss
EPS Actual
$0.24
EPS Est.
$0.62
EPS Surpr.
-60.6%
Revenue
$4.18B
Q2 FY2025
May 7, 2025Miss
EPS Actual
$0.18
EPS Est.
$0.46
EPS Surpr.
-59.5%
Revenue
$3.89B
Q1 FY2025
Jan 29, 2025Miss
EPS Actual
-$0.19
EPS Est.
$0.70
EPS Surpr.
-127.5%
Revenue
$4.23B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.39
EPS Est.
$0.66
EPS Surpr.
-158.1%
Revenue
$4.33B
Q3 FY2024
Jul 31, 2024Miss
EPS Actual
-$0.74
EPS Est.
$0.54
EPS Surpr.
-237.4%
Revenue
$4.10B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.86 | $0.88 | $0.91 | 1 |
| Q3 FY2027 | $0.83 | $0.85 | $0.88 | 1 |
| Q2 FY2027 | $0.70 | $0.72 | $0.74 | 1 |
| Q1 FY2027 | $0.62 | $0.64 | $0.66 | 1 |
| Q4 FY2026 | $0.71 | $0.72 | $0.74 | 1 |
| Q3 FY2026 | $0.44 | $0.45 | $0.46 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $4.4B | $4.5B | $4.6B | 4 |
| Q3 FY2027 | $4.4B | $4.5B | $4.6B | 5 |
| Q2 FY2027 | $4.1B | $4.2B | $4.3B | 4 |
| Q1 FY2027 | $4.0B | $4.1B | $4.1B | 4 |
| Q4 FY2026 | $4.2B | $4.3B | $4.4B | 8 |
| Q3 FY2026 | $4.2B | $4.3B | $4.4B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +10.3% | $29.19 | $29.19 | +0.00% |
| ▲ Q1 FY2026 | Jan 28, 2026 | +46.2% | $28.36 | $28.36 | +0.00% |
| ▼ Q3 FY2025 | Jul 30, 2025 | -60.6% | $14.00 | $14.00 | +0.00% |
| ▼ Q2 FY2025 | May 7, 2025 | -59.5% | $16.11 | $16.11 | +0.00% |
| ▼ Q1 FY2025 | Jan 29, 2025 | -127.5% | $19.03 | $19.03 | +0.00% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -158.1% | $17.00 | $17.00 | +0.00% |
| ▼ Q3 FY2024 | Jul 31, 2024 | -237.4% | $15.36 | $17.50 | +13.93% |
| ▼ Q2 FY2024 | May 8, 2024 | -123.5% | No price data | $15.03 | — |
Q2 FY2026+0.00%
Report Date
Apr 29, 2026
EPS Beat/Miss
+10.3%
Price Before
$29.19
Price After
$29.19
Q1 FY2026+0.00%
Report Date
Jan 28, 2026
EPS Beat/Miss
+46.2%
Price Before
$28.36
Price After
$28.36
Q3 FY2025+0.00%
Report Date
Jul 30, 2025
EPS Beat/Miss
-60.6%
Price Before
$14.00
Price After
$14.00
Q2 FY2025+0.00%
Report Date
May 7, 2025
EPS Beat/Miss
-59.5%
Price Before
$16.11
Price After
$16.11
Q1 FY2025+0.00%
Report Date
Jan 29, 2025
EPS Beat/Miss
-127.5%
Price Before
$19.03
Price After
$19.03
Q4 FY2024+0.00%
Report Date
Nov 6, 2024
EPS Beat/Miss
-158.1%
Price Before
$17.00
Price After
$17.00
Q3 FY2024+13.93%
Report Date
Jul 31, 2024
EPS Beat/Miss
-237.4%
Price Before
$15.36
Price After
$17.50
Q2 FY2024—
Report Date
May 8, 2024
EPS Beat/Miss
-123.5%
Price Before
—
Price After
$15.03
Avg Beat Reaction+0.00%
Avg Miss Reaction+2.79%
Beat Rate2 / 8 quarters
Largest Move+13.93% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TEVJF ends December
Teva Pharmaceutical Industries Limited (TEVJF) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $0.50 — beating the analyst consensus of $0.45 by +10.3%. TEVJF has beaten EPS estimates for 2 consecutive quarters. The next TEVJF earnings date is expected around September 1, 2026.
Each quarter, investors track TEVJF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TEVJF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TEVJF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TEVJF earnings · 5 questionsTeva Pharmaceutical Industries Limited's next earnings report is expected around September 1, 2026. TEVJF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TEVJF historically reports after market close (AMC).
TEVJF earnings datewhen is TEVJF earningsTEVJF next earnings datewhen does TEVJF report earningsTEVJF earnings calendar
▸ Source: FMP · Teva Pharmaceutical Industries Limited SEC filings · US GAAP · Teva Pharmaceutical Industries Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026